We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.
- Authors
Mu, Alex; Weinberg, Erica; Moulin, Dwight E.; Clarke, Hance
- Abstract
<bold>Objective: </bold>To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain.<bold>Quality Of Evidence: </bold>A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement.<bold>Main Message: </bold>Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.<bold>Conclusion: </bold>Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.
- Subjects
CANADA; ANALGESICS; PAIN management; CHRONIC pain; CONSENSUS (Social sciences); MEDICAL societies; NEURALGIA; SYSTEMATIC reviews; DISEASE complications
- Publication
Canadian Family Physician / Médecin de Famille Canadien, 2017, Vol 63, Issue 11, p844
- ISSN
0008-350X
- Publication type
journal article